It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Hallucinations are a core feature of psychosis and common in Parkinson’s. Their transient, unexpected nature suggests a change in dynamic brain states, but underlying causes are unknown. Here, we examine temporal dynamics and underlying structural connectivity in Parkinson’s-hallucinations using a combination of functional and structural MRI, network control theory, neurotransmitter density and genetic analyses. We show that Parkinson’s-hallucinators spent more time in a predominantly Segregated functional state with fewer between-state transitions. The transition from integrated-to-segregated state had lower energy cost in Parkinson’s-hallucinators; and was therefore potentially preferable. The regional energy needed for this transition was correlated with regional neurotransmitter density and gene expression for serotoninergic, GABAergic, noradrenergic and cholinergic, but not dopaminergic, receptors. We show how the combination of neurochemistry and brain structure jointly shape functional brain dynamics leading to hallucinations and highlight potential therapeutic targets by linking these changes to neurotransmitter systems involved in early sensory and complex visual processing.
The examination of temporal dynamics in Parkinson’s-hallucinations reveals that the combination of neurochemistry and brain structure jointly shape functional brain dynamics leading to hallucinations.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details



1 University College London, Dementia Research Centre, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
2 University of Cambridge, Division of Anaesthesia, School of Clinical Medicine, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934); University of Cambridge, Department of Clinical Neurosciences, Cambridge, UK (GRID:grid.5335.0) (ISNI:0000000121885934)
3 University College London, Division of Psychiatry, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
4 University College London, Huntington’s Disease Centre, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
5 University College London, Reta Lila Weston Institute of Neurological Studies, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)
6 University College London, Dementia Research Centre, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201); University College London, Wellcome Centre for Human Neuroimaging, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201); University College London, Movement Disorders Consortium, London, UK (GRID:grid.83440.3b) (ISNI:0000000121901201)